Alkermes plc. income statement ALKS

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Alkermes plc. reported revenue of $1.5 billion, down 5.2% from the year before. Net income was $241.7 million, a profit margin of 16.4%. Operating income came to $254.0 million, an operating margin of 17.2%. Diluted earnings per share were $1.43. Over the twelve months ended Sep 30, 2026, revenue was $1.8 billion and the net loss was $351,000. Across the 10 fiscal years shown, revenue grew from $745.7 million in fiscal 2016 to $1.5 billion in fiscal 2025, about 7.9% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	1,754 +15.3%	1,476 -5.2%	1,558 -6.4%	1,663 +49.6%	1,112 -5.3%	1,174 +13.0%	1,039 -11.3%	1,171 +7.0%	1,094 +21.1%	903 +21.1%	746 +18.7%
Cost of revenue	300 +41.3%	196 -19.9%	245 -3.0%	253 +16.0%	218 +10.5%	197 +10.7%	178 -1.1%	180 +2.2%	176 +14.0%	155 +17.1%	132 -4.9%
Gross profit	1,453 +11.0%	1,279 -2.5%	1,312 -7.0%	1,410 +57.8%	894 -8.5%	976 +13.5%	860 -13.1%	991 +7.9%	918 +22.6%	749 +22.0%	614 +25.4%
Research and development	430 +48.9%	324 +32.1%	245 -9.4%	271 -0.7%	273 -6.3%	291 -26.3%	395 -23.1%	513 +20.6%	425 +3.0%	413 +6.6%	387 +12.4%
Selling, general and administrative	878 +32.8%	702 +8.7%	645 -6.5%	690 +16.8%	591 +7.5%	550 +2.0%	539 -10.1%	599 +13.9%	526 +24.9%	422 +12.7%	374 +20.1%
Operating expenses	—	1,025	—	—	—	—	—	—	—	—	—
Operating income	64 -82.1%	254 -39.6%	421 +1.6%	414 +6901.1%	-6 -106.2%	98 +186.9%	-112 +35.9%	-175 -77.0%	-99 +33.0%	-148 +29.1%	-209 +7.0%
Interest income	32 -27.1%	45 +6.7%	42 +37.6%	31 +304.4%	8 +216.8%	2 -65.4%	7 -50.2%	14 +51.3%	9 +98.7%	5 +23.9%	4 +12.7%
Interest expense	87 +1764.1%	12 -45.6%	23	—	—	—	—	—	—	—	—
Other non-operating income (expense)	1 -49.7%	4 +37.8%	3 +862.8%	-0 -120.0%	2 +868.9%	0 -98.4%	14 +1509.0%	1 +141.6%	-2 +78.8%	-10 -286.9%	-2 -16666.7%
Pretax income	11 -97.2%	291 -34.3%	444 +5.3%	422 +1454.1%	-31 -135.5%	88 +190.9%	-97 +51.0%	-197 -55.2%	-127 +11.4%	-143 +33.2%	-214 +4.3%
Income tax	12 -81.5%	50 -30.5%	72 +173.3%	-98 -4924.0%	2 -82.1%	11 -20.9%	14 +3385.3%	-0 -103.5%	12 -15.9%	15 +346.9%	-6 -288.2%
Net income	-0 -100.1%	242 -34.2%	367 +3.2%	356 +324.8%	-158 -228.6%	-48 +56.6%	-111 +43.6%	-197 -41.1%	-139 +11.8%	-158 +24.2%	-208 +8.2%
Basic EPS	-0.00 -100.1%	1.47 -33.8%	2.22 +3.7%	2.14 +320.6%	-0.97	—	—	—	—	—	—
Diluted EPS	-0.00 -100.1%	1.43 -34.1%	2.17 +3.3%	2.10 +316.5%	-0.97	—	—	—	—	—	—
Weighted average shares, basic	167 +1.7%	165 -0.4%	165 -0.5%	166 +1.5%	164	—	—	—	—	—	—
Weighted average shares, diluted	168 -0.1%	169 -0.3%	169 -0.3%	170 +3.7%	164	—	—	—	—	—	—
Other measures
Depreciation and amortization	81 +167.6%	27 -4.8%	29 -61.9%	75 -3.8%	78 -1.0%	79 -3.9%	82 +1.8%	80 -22.4%	104 +5.2%	99 +4.5%	94 +10.1%
EBITDA	145 -62.7%	281 -37.4%	449 -8.2%	489 +581.4%	72 -59.3%	176 +677.0%	-31 +67.8%	-95 -2197.7%	5 +109.2%	-49 +56.8%	-114 +17.5%
Interest coverage	0.74x	20.69x	18.63x	—	—	—	—	—	—	—	—
Margins
Gross margin	82.89%	86.69%	84.25%	84.79%	80.39%	83.19%	82.83%	84.59%	83.88%	82.87%	82.28%
Operating margin	3.66%	17.21%	27.00%	24.90%	-0.55%	8.33%	-10.82%	-14.99%	-9.06%	-16.37%	-27.98%
Pretax margin	0.65%	19.75%	28.49%	25.34%	-2.80%	7.47%	-9.29%	-16.83%	-11.60%	-15.86%	-28.75%
Profit margin	-0.02%	16.37%	23.57%	21.39%	-14.24%	-4.10%	-10.67%	-16.79%	-12.73%	-17.48%	-27.95%
EBITDA margin	8.26%	19.05%	28.84%	29.40%	6.46%	15.03%	-2.94%	-8.12%	0.41%	-5.47%	-15.34%
Effective tax rate	103.10%	17.08%	16.14%	-23.16%	—	12.91%	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ALKS (Nasdaq)
Fiscal year ends: December 31
Headquarters: Dublin 4, Ireland
SEC filer status: Large accelerated filer
SEC CIK: 1520262
Former names: ANTLER SCIENCE TWO PLC (until Aug 5, 2011); Antler Science Two Ltd (until Aug 2, 2011)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.